rate share outperform base rel attract anim health
market solid outlook top- bottom-lin growth versu market
upsid potenti f/t/hw oral tripl trio diagnost expans asf rebound
inject pain mab cats/dog review believ execut
prospect move share higher
estim sale driven new product abaxi
diagnost acquisit ep estim revenu growth
per year leverag ep gain rais price target
estim ep improv top bottom line visibl
zoeti current blockbust products/brand sale
canin atop dermat product apoquel oral cytopoint inject
mab estim sale combin product
oral flea tick product simparica approv februari sale
estim forecast includ line
extens tripl combo trio expect approved/launch late
 zoeti target increment sale similar
anim health compani visibl zoeti pipelin limit shown abil
innov import new agent
african swine fever asf highli contagi deadli viru affect pig harm
human dampen sale china global leader pork product
impact zoeti estim approxim loss off-set
combin sale swine produc region protein poultri fish beef
strength companion anim sale believ could boost futur sale
asf supply/demand dynam play affect area ultim contain viru
rebuild herd
august zoeti announc file felin mab oa pain file
canin version announc octob launch product expect
companion anim pain market estim kol think could
potenti doubl cat dog inject pain option
pleas see page report import disclosur
estim revenu ep includ
full year abaxi close gpm forecast increas despit
impact initi lower gpm abaxi favor price mix fx trend
contribut higher-than-expect margin sg estim increas
expand field forc diagnost new product launch increas
drive oper margin expans estim net
interest/oth expens increas fund abaxi acquisit
tax rate increas share declin
manag indic abaxi transact mildli accret
cowen compani
estim revenu ep gpm forecast
increas ahead manag target
improv driven larg mix shift profit companion
anim sale sg estim increas increas drive
oper margin expans estim net interest/oth expens
hold flat tax rate increas share declin
forecast annual revenu growth upper end expect
market trend upsid possibl new products/acquisit assum gpm
hold estim sg growth growth
fuel oper margin expans year assum
zoeti guidancecowen estim revapproxim exp/oth netapproxim rate approxim incom assum growth ex fx ex fx abaxisbold revis
stabl tax rate declin share per year forecast ep
may zoeti announc major oper restructur streamlin
oper emphas key product lines/region initi temper sale
growth due elimin total sku smaller
presenc region venezuela oper margin expand
shift higher margin product region well
expens reduct initi greater use distributor streamlin
manag structur other number direct sale market declin
account total revenu use distributor increas
market market includ combin direct sale
distributor zoeti select increas number product
parasiticid expand distributor relationship
zoeti cash/equival short-term invest zero
short-term debt long-term debt estim free cash flow oper cf
minu capital-expenditure expand annual support
annual dividend payment well modest annual share
repurchas bolt-on acquisit
cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg /human ww lc ex total dog mfg /human revenu
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg/human ww lc ex total total dog
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock cattl beef dairi swine poultri apoquel cytopoint simparica dx new product drive growthtot ahead market growth revenu driven demand protein especi em livestock lc ex pharmaq farm fish ad companion new product expand pet care dx companion lc ex -restructur lc ex revenu line market growth speci cer new product key apoquel cytopoint simparica contract mfg /human tie former contract abaxi human dx ad aug ww lc ex strong em demand safe protein beef dairi solid demand asf impact on-going steadi demand trend toward antibiotic-fre farm fish ad pharmaq sheep othertot speci trend vari geographicallycompanion total dog new product abaxi line extens drive growth nich markettot could even faster given potenti influx new drugscontract mfg /human activ pursuedtot revenu steadi gain upsid possibl
compani data cowen compani
ceftiofur rev market sinc draxxin rev market sinc anti-infect sku reduct exclud growth promot livestock fish companion anim product parasiticid revolut price/or competit mainli felin use nich dog simparica oral flea tick launch eu topic felin trio review parasiticid mostli livestock fishparasiticid boost pharmaq ionophor grow off-set ractopamin shared-us anti-bio declinesoth product apoquel atop dermat dog expand acute/season use cytopoint canin atop dermat inject total pharma rimadyl sileo surgic med nexvet mab pharma undisclos pipelin product could boost genet test iv fluid embrex devic anim hlth companion anim dx abaxi close product assum small bolt-on acquisitionscontract product suppli agreementstot fx estim
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg/human ww lc ex total total dog
compani data cowen compani
pharma includ wide rang product includ apoquel cytopoint
canin atop dermat rimadyl nsaid dog gener sinc veterinari
surgic suit product palladia mast cell tumor dog lutelys estrou
synchron dairi cattl sileo canin nois avers mani drug
livestock companion anim
zoeti acquir nexvet leader develop mab
canine/felin oa pain august zoeti announc submiss regulatori
file felin pain mab plan file canin version soon expect
inject mab signific driver pharma growth start near
term platinum perform lead provid nutrition-focus product
equin market zoeti acquir juli add boost sale
anticip pharma segment grow
upsid possibl fuel new drug bolt-on acquisit collabor
apoquel oclacitinib first oral inhibitor approv veterinari use
target itch inflamm dog approv may
eu septemb indic control itch associ
allerg dermat control atop dermat dog least month old
itch second common reason canin vet visit antihistamin
steroid usual treatment although low efficaci side effect
limit use agent apoquel first drug specif target
reduc itch apoquel tablet given twice day two week daili
mainten requir tablet avail three strength tablet current
cost approxim vet post earli price increas
retail charg pet owner per tablet
apoquel launch uk germani certain market
initi demand exceed expect switch therapi faster
anticip suppli shortag develop quickli manufactur process
complex requir month raw materi finish good avail
limit dog apoquel get prioriti shipment new patient start
restrict manufactur process improv made suppli increas
april constraint persist due consist issu larger batch
late correct measur taken includ second api
supplier full avail announc april restrict remov
outsid apoquel launch major market includ china
approved/launch april/may estim apoquel sale
approxim dog estim
atop dermat itching/inflamm approxim half
dog estim well care thu potenti candid apoquel
treatment zoeti estim canin itching/inflamm consist three type
chronic therapi durat day estim total acut
therapi durat week season treatment durat
apoquel initi target dog chronic itching/ inflamm
greatest need suppli issu resolv zoeti reach
shorter use segment acut season itch part effort dtc
advertis campaign launch favor feedback
continu also expect lcm initi support longer term prospect
compani data cowen compani estim
dog own dog live longer ownership satur dog w/atop derm relat total dog could higher well-cared-for dog w/ad assum owner pay better care dog w/ chronic ad assum chronic prior share may declin cytopoint captur greater share share dog treat per price hike estim per year tabs/day start tab qd doses/yr apoquel sale mm dog treat per inject price hike estim per year inject assum shots/yr cytopoint sale mm dog w/ season ad assum season prior share dog treat per price hike estim per year tab qd day twice/yr doses/yr apoquel sale mm dog w/ acut ad assum acut prior share dog treat per price hike estim per year tab qd week doses/yr apoquel sale mm apoquel sale driven market expans assum competit apoquel ou sale major countri launch china yet approv largest ou countri sale ww apoquel sale cytopoint sale cytopoint ou sale ww cytopoint sale derm sale ou derm sale total ww derm sale
august zoeti receiv condit approv cytopoint lokivetmab anti il-
mab treatment canin atop dermat full approv receiv
late decemb full approv also receiv canada march eu
april septemb label updat includ allerg dermat
approv indic cytopoint administ sc everi
week use pattern appear averag week approv dog
age treat itch associ atop dermat eu approv
dose administ everi week cost per vial vet rang
depend size dog cost patient typic doubl vet
cytopoint provid anoth treatment option along apoquel expand zoetiss
presenc ad market uptak strong reflect potenti altern
dog intolerant/not-respond apoquel prefer pet owner
monthli inject assur compliance/less hassl daili pill favor
vet benefit ad monthli visit zoeti estim approxim
cytopoint sale apoquel user remain new patient
estim cytopoint sale
zoeti estim dermatolog portfolio apoquel cytopoint
use treat dog dermatolog condit given favor
uptak zoeti estim combin sale dermatolog portfolio
apoquel cytopoint would reach actual sale came
august manag indic derm sale expect top
ou growth remain key driver penetr
rate much lower recent apoquel approv china could add
upsid outlook apoquel patent expir cytopoint
expect competit apoquel/cytopoint next coupl year although kol
believ first-mov advantag extraordinari effect entrench
product vet owner commun potenti competitor face
uphil battl estim dermatolog portfolio sale
also note season derm
busi stronger sale warmer weather
juli zoeti acquir nexvet biopharma cash
approxim nexvet focus sole biolog companion anim
use proprietari process rapidli effici identifi speci specif mab
time acquisit lead mab oa pain ranevetmab dog
frunevetmab cat estim file mid-lat
august zoeti announc file felin mab oa pain file
canin version announc octob product anticip
launch zoeti indic felin mab frunevetmab canin mab
file ranevetmab zoeti develop one biolog nexvet
conjunct zenoaq also agent evalu
mab nexvet pipelin target inflamm allergi
canine/felin pain market estim roughli major
spent nsaid small portion opioid howev market could
significantli larger amount reflect avail treatment vet kol
discuss cowen march confer indic
patient dogs/cat unabl take nsaid owner allow
use particular repres signific unmet need avail
treatment chronic pain potenti cat chronic pan
vet kol surgeon pain specialist see mab pain answer earli
stage work ngf mab result spectacular improv seen
safeti efficaci nsaid ngf mab non-or long durat
inject everi week make especi ideal cat safeti issu
ngf rpoa osteonecrosi seen dogs/cat also
sign liver kidney stomach advers effect efficaci appear
nsaid besid zoeti compani also believ work pain
mab kol note ztss cytopoint mab atop dermat help
increas vet comfort level prescribing/administ mab note
cytopoint sale reach blockbust statu year post
june zoeti announc collabor regeneron research
use regeneron mab anim financi term disclos zoeti
licens velocimmun antibodi technolog potenti develop mab
companion anim livestock rang therapeut area includ allergi
immunolog pain inflamm cancer regeneron elig licens fee
mileston royalti commerci treatment regeneron also select
specifi antibodi zoeti pipelin evalu canine/felin data help
predict potenti use human collabor provid zoeti addit
tool expand develop anim biolog
februari zoeti acquir abbott anim health busi
acquisit includ product use veterinari surgic suit diagnost devic
agent treat cancer pain dog primari surgic area product
surgeri intraven fluid relat products/equip non-surg
product includ alphatrack home glucos monitor system use diabet
dog cat paccal paclitaxel inject condit approv
mammari squamou cell carcinoma dog pain product orocam nsaid
meloxicam administ oral spray disclos estim abbott ah
sale sale report
pharma non-pharma categori
non-pharma product includ anim diagnost abaxi non-diagnost
non-pharma product includ genet product breed servic beef
dairi cattl surgic suit suppli devic acquir abbott health
non-drug product poultri devic ovo vaccin deliveri system
acquisit like segment could add upsid growth project
recent acquisit smartbow small austrian compani
develops/market digit eartag dairi cattl eartag enabl anim
identif behavior monitor use rfid data analyt
allow farmer monitor movement heat rumin behavior cattl
zoeti anticip opportun develop data digit product
estim non-pharmaceut ex diagnost revenu
diagnost view key part portfolio virtual treatment
prevent requir diagnost intervent thu complementari core
busi zoeti point equip refer lab product in-hous
initi fairli small august zoeti acquir privat held
scandinavian micro biodevic smb smb provid point-of-car
diagnost proprietari lab chip microfluid platform primarili companion
anim smb market quickvet analyz cartridg coagul fibrinogen
blood type product integr abaxi portfolio
februari zoeti announc launch carysta high-volum chemistri
hvc system high-volum veterinari practic carysta menu routin
specialti test
juli zoeti acquir abaxi veterinari diagnost provid cash
significantli boost footprint diagnost market abaxi provid
veterinari chemistri hematolog point care diagnost instrument relat
consum primarili companion anim market march revenu
transact expect mildli accret
accret larg driven leverag abaxi product line global
infrastructur zoeti reiter acquisit impact target goal
gpm improv estim anim diagnost sale
companion anim time
estim ww anim diagnost market compound-annual-growth-rate past
year anticip diagnost sale grow compound-annual-growth-rate next
year point care product line current focus companion anim
see eventu opportun product anim well
augment grow diagnost busi zoeti expand
refer lab busi octob zoeti acquir phoenix lab
sizabl presenc pacif northwest novemb zoeti acquir znlab
refenc lab compani network across hub louisvil spoke
bois chicago cincinnati dalla new orlean lake citi zoeti continu
expand refer lab space combin addit small
acquisit intern develop
vaccin demand remain strong companion product anim companion
anim vaccin expect grow medic expand global livestock
healthi anim keep product cost limit need antibiot
becom increasingli import although asf challeng cattl market
dampen growth zoeti also view abil quickli identifi
pathogen respons outbreak provid vaccin rapidli possibl
occur pedv key differenti strategi zoeti activ
develop vaccin african swine fever although still earli stage
septemb zoeti enter non-exclus agreement usda provid
access three patents/materi relat asf zoeti incorpor
research given challeng characterist pathogen progress
vaccin develop like take sever year
late pharmaq acquisit provid new growth avenu farm fish
segment mani new product launch expect next coupl year joint
ventur china jilin guoyuan expand livestock vaccin portfolio recent
approv includ swine fever marek poultri new vaccin facil
suzhou complet late await regulatori certif zoeti
introduc new poultri vaccin product vector vaccin use hatcheri initi
 expand countri first vaccin poulvac procerta
hvt-nd protect vs marek newcastl approv octob
estim vaccin sale
novemb zoeti acquir pharmaq ww leader farm fish product
primarili vaccin parasiticid sale
pharmaq sale estim
aquacultur market estim grow close
farm fish repres global fish product pharmaq global presenc
salmon estim market share salmon vaccin robust late stage
pipelin includ product emerg farm speci tilapia catfish
made attract addit zoeti portfolio elanco also
expand aquacultur
pharmaq sale includ vaccin parasiticid segment august
pharmaq announc collabor vinh hoan hq vietnam lead
produc export pangasiu larg freshwat catfish pharmaq provid
alpha ject panga vaccin well services/product
diseas outbreak vari speci viral strain geographi provid
on-going need new vaccin outbreak porcin epidem diarrhea viru pedv
 exampl pedv first report april spread
state kill piglet reduc herd size increas valu
remain herd pedv harm human minim impact older
pig summertim impact less viru activ cold weather
earli septemb approxim month outbreak first
report zoeti receiv condit approv pedv vaccin vaccin
administ sow gilt two dose im inject three week apart
second dose given two week farrow pedv factor
african swine fever latest signific diseas outbreak vaccin
zoeti activ work develop although commerci vaccin
appear immin asf discuss detail later
parasit use wide livestock companion anim parasiticid sale
pressur companion side due competit pressur core
revolution/stronghold topic flea/tick brand impact new oral flea tick
product boehring ingelheim merck howev later zoeti receiv eu
approv oral canin product simparica canadian approv
grant earli provid boost companion anim parasiticid sale
livestock side zoeti continu strong presenc dectomax
cydectin product market year remain strong
account roughli sale estim parasiticid sale
compound-annual-growth-rate growth
driven larg simparica line extens trio farm fish product
pharmaq
novemb zoeti gain eu approv oral canin flea tick product
simparica sarolan approv receiv februari launch
region began april bit late start season simparica
third oral flea tick product market behind bi nexgard approv
eu merck bravecto approv eu elanco credelio
market approv eu
simparica chew tab given monthli like nexgard bravecto given everi
month simparica studi demonstr faster time kill flea tick
compar nexgard deer tick indic ad label late
simparica give zoeti presenc fast-grow oral segment
ww companion anim parasiticid market help off-set declin topic
revolut line simparica price discount nexgard
simparica backbon zoeti flea tick portfolio mani
combin product heartworm agent felin version expect
launch come year first combo product stronghold
approv eu februari stronghold felin topic
combo simparica revolut selamectin provid once-monthli topic
treatment flea tick heartworm cat product approv
late launch earli revolut also juli proheart
inject formul revolut protect dog heartworm
year approv current approv one year
inject heartworm
simparica trio sarolan moxidectin pyrantel embon cover flea tick
mite intern parasit heartworm file approv
expect late launch shortli price signific premium
simparica approv eu canada grant launch
market plan trio also review brazil australia japan china
mexico market repres greatest opportun zoeti target
increment sale trio assum unquantifi
cannib exist f/t/hw product also assum trio
indic use puppi simparica alon indic dog month
industri kol note f/t/heartworm product commonli use
recommend durat thu under-dos although specif rate vari significantli
region commerci tripl may address complianc issu
potenti broaden market expand awar howev kol less
convinc signific inroad made believ certain exist
heartworm product strong brand loyalti conveni aspect
give one oral instead two less import simaprica sale
estim product formul conserv compani
estim simparica franchis sale
includ formul combin
product label compani data cowen compani data
zoeti blockbust brand includ ceftiofur draxxin inject
antibiot livestock account sale ceftiofur
market year maintain strong market posit
enhanc year improv formul deliveri option inject
anti-infect use growth promot oral lower dose
use treat/prev bacteri infect demand expect overal
bravecto nexgard bi simparica credelio dosageeveri month monthlymonthlymonthlyg foodwith with/without with/without withminimum mo week mo weeksminimum weight lb lb lb lb time start kill flea hour hour hour hoursflea ctenocephalid felisxxxxtick amblyomma americanum lone tick xxx amblyomma maculatum gulf coast tick -- -- -- dermacentor variabili american dog tick xxxx rhipicephalu sanguineu brown dog tick xxxx ixod scapulari black-legged/d tick xxxxu approv may octob februari januari approv march februari novemb april per everi week lone tick exposur base price on-lin pet-stor price vari dog weight packag size price vet offic may higher
fairli stabl estim anti-infect sale
compound-annual-growth-rate
medic food addit use decad includ wide rang
agents/med ad food/wat product anim
use control/prev infect bacteri parasit provid nutrit
maintain feed integr sizabl debat use
addit particularli antibiot beta-agonist zilpaterol ractopamin due
potenti neg impact human anim particular low-dos antibiot
use poultri pressur rel short life span broiler
approxim week birth consumpt limit time need
maintain anim health make econom feasibl avoid use
antibiot mfa rel swine month birth product especi cattl
januari vfd veterinari feed direct discuss becam
effect full year ztss livestock sale neg impact
approxim vfd reduct base
materi impact seen believ use growth promot beta-
agonist low-dos anti-infect continu declin product
vaccin non-human antibiot synthet anticoccidi ionophor nex-gen
growth promot gain increas use estim sale
flat compound-annual-growth-rate
antibiot often use feed treat/prev infect addit feed
human effici method treat group anim antibiot
also use promot growth although exact mechan action known
livestock farmer deriv benefit infect prevent growth howev
increas resist bacteri strain human call question use
antibiot food anim scientif data indic restrict use anim feed
help limit growth resist strain human appear ideal solut
would restrict antibiot shorter-term higher-dos treatment/prevent
role disallow use growth promot longer term lower dose howev
distinct difficult enforc oppon seek complet banish antibiot
feed propon want least limit use
decemb fda announc plan judici use polici phase
use medic import antibiot includ penicillin tetracyclin macrolid
use product anim feed/wat promot weight gain/fe effici anti-
microbi human equival ionopher exclud polici
direct antibiot manufactur voluntarili remov growth enhanc
feed effici indic medic import drug product move
therapeut use product over-the-counter market statu requir
affect product use food-produc anim treat
prevent control diseas order licens veterinarian compani
market antibiot agre plan
zoeti estim low dose antibiot immateri
portfolio although expect continu util feed/wat
antibiot treat infect prevent diseas potenti offset less shared-class
antibiot use would greater use non-med import anti-infect
ionophor synthet anticoccidi vaccin help prevent ill well
develop new antibiot shared-us human
zoeti indic interest develop
zoeti activ seek innov livestock includ antibiot altern
immunotherapi precis farm genet breed healthier product
earli zoeti launch swine actogain cattl enhanc
weight gain feed effici activ ingredi ractopamin beta agonist
paylean/optaflexx elanco/lilli demand ractopamin increas
initi merck halt sale zilmax beta-agonist zilpaterol august
howev ractopamin ban countri ww includ eu russia
china ban implement lack data prove safeti human well
anim welfar concern trade negoti unsuccess tri elimin
ban eu unit nation safeti panel confirm safeti ractopamin
chang ban place eu russia china
ractopamin legal canada mexico japan south korea number
countri mani food produc move ractopamine-fre pork/beef
asf modest near-term overhang larg anim health compani
swine herd china cull combat highli contagi viral diseas
harm human china global leader pork product consumpt
reduc swine headcount dampen current anim health product sale
larg market howev pork suppli ramp region herd rebuild affect
area demand protein chicken beef fish increas anim compani
sale may get boost novemb zoeti indic global pork
price risen significantli brazil eu particularli well posit
benefit dynam
asf short-term neg anim health sale due reduc swine headcount
largest supplier pork meat china fewer parasiticid vaccin anti-
infect need asf yet appear contain china latest data
detail suggest signific swine loss continu china spread
meaning neighbor area vietnam downward
revis swine headcount affect area remain possibl given lack viral
contain possibl spread area addit cull quit possibl
would add addit pressur near term product sale
asf sale impact
compani data cowen compani
howev outbreak like provid long-term boost anim health
compani product need keep uninfect swine healthi grow
valu uninfect herd increas suppli increas countri
boost product sale also like increas
demand protein chicken fish beef also posit sale
china specif herd rebuild eventu requir addit product
especi swine farm becom larger industri also note
multi-national anim health compani account sale present
suggest plenti room growth increas product demand tariff discuss
country-specif restrict certain protein import add layer complex
make difficult precis estim time magnitud potenti sale gain
african swine fever asf highli contagi viral asfiviru hemorrhag diseas
affect domest feral pig eurasian wild boar
differ genotyp wide rang virul diseas endem africa
warthog bush pig act host sign diseas asf also
transmit specif soft tick asf affect human industri expert
indic china begin test pork asf sold public
appear part effort stop viral spread food-rel wast
transmiss occur direct contact infect pig secret blood
tissu ingest contamin pork product may fed pig cloth
equip etc vector soft tick viru resist environ
last day fece month preserv pork product month
blood year frozen carcass make certainti remov difficult
viru kill cook meat
incub period viru day direct contact day
tick bite form asf peracut sudden death acut subacut
chronic clinic sign acut asf includ high fever anorexia lethargi weak
erythema cyanosi hemorrhag skin snout diarrhea respiratori problem
death day subacut chronic diseas similar symptom milder
death recoveri week sub-acut diseas age pig affect
asf unlik pedv affect piglet
asf viru first discov kenya first occurr outsid africa
report portug outbreak spain/portug
part europ asf erad
report part russia eastern european area poland romania
other local outbreak continu occur
sale mm mm total mm china sale estim china sale estim china swine sale estim asf sale impact mm
august asf report first time china domest pig
accord world organ anim health asf incid peak china
late earli howev challeng get accur outbreak data
china bi-weekli updat provid world organ anim health
indic continu outbreak asia europ latest data show
greatest increas new outbreak time-frame vietnam
romania howev report captur voluntari self-report submiss
leav door open misrepresent well incomplet data
asf never report canada mexico australia/nz howev
usda believ illeg entri swine products/by-product offer
like potenti path entri asf viru specif via air passeng
baggag contamin product perhap foreign mail industri expert
believ asf eventu find way would shut
pork export immedi significantli chang anticip impact
protein market howev also note market consist mainli larger
industri farm biosecur prevent measur higher
standard viral contamin less like
current treatment vaccin asf infect swine need
quarantin cull farm fulli steril especi challeng given
high resist viru prevent requir direct avoid contact
feral pig indirect feed uncook pork product pig disinfect
everyth correct dispos manure/ carcass prevent vector
media report indic vaccin develop
china although still appear year away vaccin initi evalu
 develop languish due lack fund technic
challeng viru african swine fever task forc establish
 depart homeland secur focu improv diagnost
vaccin potenti diagnost improv includ method rapid
sampl collect improv method isol asf viru vaccin candid
evalu task forc promis candid transfer
industri partner develop zoeti indic activ
work vaccin
china largest pork produc countri world far account roughli
global product eu next howev
usda estim china repres total drop
octob usda estim global pig crop reduc
time million hog april project time
reduc hog prior estim china compris virtual
downward revis chines hog product estim declin
declin project
industri expert note gener expect reduct
pork product due asf note china alreadi process larg
amount pork begin year avoid potenti infect much
pork cold storag may start deplet
entir pig regener process take approxim month consist
period young femal pig matur breed age month
gestat month grow post-birth sow adult femal pig produc
litter per year around piglet expert note sow
liquid china estim mid-point would repres
month market hog reduct roughli head without diseas loss
regener china hog popul fluid affect produc must cull herd
includ sow clean infect area support new product increas anim
safety/welfar cost prevent spread diseas challeng access
capit china hog produc reason restock effort could delay
usda foreign agricultur servic estim small hog produc account
chg y/yproduct pig crop head
nearli half china hog product expert note commerci
farm heads/farm account total
heads/farm heads/farm also note larg skew
smaller size preval small farm gener less biosecur along
unclear void china hog product fill expert note
pork export around world could fill chines gap usda
estim revis octob show increas pig crop russia
brazil mexico nearli enough make china shortfal usda
suggest expect global suppli begin catch produc
gain better albeit still accur sens big shortfal china
market price react expert concur expect impact asf
signific beyond
usda livestock poultri world market trade octob
demand perspect expert note pork domin protein
consum china lb /capita follow poultri lb /capita beef
lb /capita note shortag pork like result china consum
like switch poultri eat less pork beef afford option
fish would anoth altern top pork import china
germani spain canada brazil distant although like
indirect benefit export increas countri sell directli china
countri whose demand longer met supplier focus increas
china need would true poultri top china broiler import
brazil hong kong argentina import restrict sinc avian
flu outbreak re-open novemb enabl produc
benefit increas poultri demand china
note sizabl geograph divers could
potenti enabl captur sale china key market
directli indirectli benefit asf chang impact china pork market
zoetiss sale estim livestock companion anim
overal market roughli livestock companion anim abaxi
acquisit companion anim growth apoquel new companion drug
simparica cytopoint eventu nexvet mab expect shift mix
companion product companion anim sale forecast top livestock sale
compani data cowen compani estim
estim livestock sale grow driven underli strong
demand safe protein current pressur asf outbreak factor
influenc livestock sale weather diseas econom dynam especi
emerg market trade agreements/negoti estim companion sale
grow quickli driven new product includ abaxi
although segment also reflect econom sensit
may zoeti revis estim global anim health market
ex fx novemb due african swine fever
cattl beef dairi overal averag poultri companion
anim rel line overal market growth zoeti expect sale
market trend companion anim swine in-lin poultri
cattl zoeti expect market growth return normal rate
usda forecast modest increas beef cattl headcount
assumpt includ modestli increas demand strong ou demand
export over-simplifi gener anim mean anim health
product sold antibiot free grass-f cattl continu increas
trend offer opportun product vaccin non-med
import antibiot estim zoetiss beef cattl busi repres
roughli global sale cattl sale challeng year
 beef dairi cattl market dynam weather given cyclic
busi beef cattl sale expect challeng dairi cattl sale
may show recoveri still earli predict
total mm sale ww sale mm row sale ww salesproduct total animaldog total row
 cattl sale pressur neg time impact sale
shift continu difficult trend dairi ou cattl trend vari
countri australia notabl strong brazil weak due chang
pricing/pay polici strengthen long-term outlook
cattl sale declin modestli due on-going dairi pressur wet weather
impact movement beef cattl feed lot ou cattl sale increas larg
due favor y/i comparison brazil truck strike impact beef
dairi cattl sale dampen unfavor market condit lower feedlot
placement price pressur ou cattl sale grew led favor market
condit mexico uk canada partial off-set tough compar brazil
 sale neg affect discontinu promot
program premium product time sale swine sale
modestli reflect promot program ou swine sale flat
vaccin growth off-set asf swine sale time
promot ou swine sale also continu asf pressur eventu
upsid asf possibl void left reduct china pork suppli
address countri although time expand herd suggest impact may
felt beyond
ztss exposur potenti chines tariff pork modest swine sale
approxim total revenu product
export would export total china account
approxim approxim howev asf could lead
zoeti expect poultri sale grow roughli line market on-going
pressur produc elimin use medic import antibiot
boost sale altern zoamix robenz deccox synthet
anticoccidi vaccin poulevac sale robust led sale
antibiot altern product ou trend also strong driven
altern product well competitor suppli constraint sale
growth solid led ionophor competitor constraint ou sale growth
also strong led china australia brazil
fish product farm fish mainli parasiticid vaccin chile norway
key growth market pharmaq product fish sale
dog overal demand solid spend pet care medic pet
continu increas new drug apoquel cytopoint simparica
addit abaxi boost categori
companion anim sale ex abaxi ou
driven apoquel cytopoint simparica growth
respect growth
hors hors nich market primarili antibiot pain med price point
high equin sale flat sale aid new vaccin
recent platinum perform acquisit close juli like boost annual
equin sale
global anim health care sale dynam vari significantli countri speci
product zoeti salesforc combin technic team compos
veterinarian technician other veterinari skill special diagnost
personnel provid requir products/servic detail train directli
vet other along tradit salesforc larg well-train
direct sale forc key enabl zoeti consist grow ahead
market part restructur salesforc focus
attract region drive greater share profit expand use
distributor past year along direct sale help drive
share gain sever area includ
zoeti market product well repres across therapeut area
product companion anim sku reduct estim
elimin product total product ou
livestock area ye zoetiss largest singl product apoquel sale
total sale largest product draxxin tulathromycin
inject antibiot bovin swine respiratori diseas account
approxim sale ceftiofur cephalosporin line inject antibiot
livestock revolut line topic flea tick prevent dog cat
account sale combin top product account
total revenu product sale account least total revenu
product/product line sale least shown
repres total sale
livestockanti-infectivesceftiofurclavamox/synuloxdraxxinconveniaspectramastterramycinvaccinesimprovac/improvest/vivaxvanguard linesuvaxyn pcv/fostera pcvparasiticidesdectomaxproheartrevolution/strongholdsimparicamed feed additivesaureomycinbmdlasalocidlincomycinotherembrexapoquellutalysecereniacytopointrimadyl product least revenu togeth total revenuecompanion
zoeti complet number bolt-on acquisit year round
therapeut categori geographi believ similar transact remain
like go forward area view potenti target includ diagnost on-farm
diseas resist servic train food safeti pain/skin diseas
cowen compani
major zoetiss top-sel product market decad
revenu deriv product exclus ip yet averag product
durat top sell product year sustain reflect
strong brand loyalti seen veterinari product zoeti sales/servic initi
maintain strong relationship custom relationship
critic given highli diversifi payer base associ anim health on-going
line extens also import product sustain recent exampl may
 approv clavamox chewabl dog addit tablet liquid
drop formul clavamox first approv
dateacquisit beecham anim health divisionad first vaccin small anim corporationad cattl product exisit anim ad product australia inc ad poultri devic vaccin genet au nz bovigen ad anim genet includ dna technolog gene marker expertis livestock dodg anim part wyeth ad proheart dog synovex cattl equin poultri anim india emerg market internationalad first aquacultur corportationprovid entri anim diagnost part king ad poultri mfa cattl swine anim productsexpand footprint veterinari surgic settingkl productsexpand poultri devic offeringspharmaqadd ww presenc aquacultur micro biodevicesexpand diagnot first mab dog/cat oa pain digit monitor livestock sizabl diagnost performanceadd nutrition-focus equin labexpand diagnost footprint refer refer lab presenc
cowen compani
sale ou believ geograph divers posit
provid cushion weather diseas polit vagari
china remain growth focu multi-national anim health compani account
total sale grow emphasi food safeti suggest plenti
opportun market china sale repres total zoeti sale prior asf
sale grow ex fx sale ex fx declin
near term trend uncertain herd reduct timing/ext rebuild
difficult quantifi like shift larger industri farm oper
long-term posit zoeti howev companion anim sale grow
brazil sale grew ex fx driven favor export market
increas medic pet sale ex fx driven
livestock companion anim cytopoint launch asf may prompt
increas swine/poultri product brazil
sale product categoryyear marketcom singl dose inject cattl inject antibiot livestock dog cat pressur new oral nsaid gener share held skin infect cat dog singl oral amoxicillin/clavulan acid dog expect declin use becom expect declin use becom canin vaccinesembrex poultri ovo estru synchron anti-emet prevent boar taint estim sale
cowen compani zoeti
ww anim health market estim grow annual zoeti
market leader estim sale market broken
product anim companion anim product food anim primarili
livestock includ cattl beef dairi swine poultri sheep goat farm fish
product market matur demand protein emerg market
key driver growth weather diseas outbreak polit market economi
also influenc trend companion anim primarili dog cat also hors
expect sizabl influx new product mainli human drug modifi pet use
drive stronger growth compar product segment
cowen compani estim
ye countri mm livestock livestock livestock livestock livestock livestock livestock livestock livestock livestock livestock companionoth livestock companionoth livestock companion total chg y/i total demand safe protein need antibiot altern beef pork poultri farm biolog roll mani unmet need innov acceler growth per annum driven companion
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
current payabl current work cash activ net incom restructuring/one-tim depreci chang work capit activ capit acquisitions/divestitur activ total debt dividend share repurchas chang equival
compani data cowen compani estim
assumpt outputequ share outstand gross margin oper intang interest incom tax work free dcf mm cowen
